In-House, Rapid, and Low-Cost SARS-CoV-2 Spike Gene Sequencing Protocol to Identify Variants of Concern Using Sanger Sequencing
Alhamlan, F.; Bakheet, D.; Bohol, M.; Alsanea, M.; Alahaideb, B.; Alhadeq, F.; Alsuwairi, F.; Al-Abdulkareem, M.; Asiri, M.; Almaghrabi, R.; Altamimi, S.; Mutabagani, M.; Althawadi, S.; Al-Qahtani, A.
Show abstract
BackgroundThe need for active genomic sequencing surveillance to rapidly identify circulating SARS-CoV-2 variants of concern (VOCs) is critical. However, increased global demand has led to a shortage of commercial SARS-CoV-2 sequencing kits, and not every country has the technological capability or the funds for high-throughput sequencing platforms. Therefore, this study aimed to develop and validate a rapid, cost-efficient genome sequencing protocol that uses supplies, equipment, and methodologic expertise available in standard molecular or diagnostic laboratories to identify circulating SARS-CoV-2 variants of concern. MethodsSets of primers flanking the SARS-CoV-2 spike gene were designed using SARS-CoV-2 genome sequences retrieved from the Global Initiative on Sharing Avian Influenza Data (GISAID) Database and synthesized in-house. Primer specificity and final sequences were verified using online prediction analyses with BLAST. The primers were validated using 282 nasopharyngeal samples collected from patients assessed as positive for SARS-CoV-2 at the diagnostic laboratory of the hospital. The patient samples were subjected to RNA extraction followed by cDNA synthesis, conventional polymerase chain reaction, and Sanger sequencing. Protocol specificity was confirmed by comparing these results with SARS-CoV-2 whole genome sequencing of the same samples. ResultsSanger sequencing using the newly designed primers and next-generation whole genome sequencing of 282 patient samples indicated identical VOCs results: 123 samples contained the alpha variant (B.1.1.7); 78, beta (B.1.351), 0, gamma (P.1), and 13, delta (B.1.617.2). The remaining samples were not 100% identical to the reference genome; however, 99.97% identity indicated that there was minimal variation as the virus spread throughout the nation. Only four samples had poor sequence quality by Sanger sequencing owing to a low RNA count (Ct value >38). Therefore, mutation calls were >98% accurate. ConclusionsSanger sequencing method using in-house primers is an alternative approach that can be used in facilities with existing equipment to mitigate limitations in high throughput supplies required to identify SARS-CoV-2 variants of concern during the COVID-19 pandemic. This protocol is easily adaptable for detection of emerging variants.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Difference in TMPRSS2 usage by Delta and Omicron variants of SARS-CoV-2: Implication for a sudden increase among children 97%
- SARS-CoV-2 detection in multi-sample pools in a real pandemic scenario: a screening strategy of choice for active surveillance 97%
- Molecular Epidemiology of SARS-CoV-2 in Cyprus 96%
Similar papers in this journal
- Rapid and simultaneous identification of three mutations by the Novaplex™ SARS-CoV-2 Variants I Assay kit 97%
- Implementation of an in-house real-time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2 Marseille-4 variant 96%
- Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce community spread? 96%
Similar papers in this journal
- Genomics of Post-Vaccination SARS-CoV-2 Infections During the Delta Dominated Second Wave of COVID-19 Pandemic, from Mumbai Metropolitan Region (MMR), India 97%
- A rapid and cost-effective multiplex ARMS-PCR method for the simultaneous genotyping of the circulating SARS-CoV-2 phylogenetic clades 96%
- Viral loads and profile of the patients infected with SARS-CoV-2 Delta, Alpha or R.1 variants in Tokyo 96%
Similar papers in this journal
- The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan 97%
- Clinical Evaluation of a Combo Rapid Antigen Test QuickNavi-Flu+COVID19 Ag for Simultaneous Detection of SARS-CoV-2 and Influenza Viruses 96%
- Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2 96%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.